- Andexanet alfa Reduces Hematoma Expansion Following Controlled Cortical Impact in Mice Pretreated with Rivaroxaban
Neurocritical Care · 2026
- Medication Adherence and Antithrombotic Therapy Outcomes
JACC Asia · 2026
- Adrenal hemorrhage requiring apixaban reversal in the setting of active deep vein thrombosis and heparin-induced thrombocytopenia: A case report
American Journal of Health-System Pharmacy · 2026
- Patient perspectives on post-operative direct oral anticoagulant for venous thromboembolism prevention in patients with gynecologic cancers undergoing laparotomy
Gynecologic Oncology Reports · 2026
- Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose‐reduction better for all?
HemaSphere · 2026
- Andexanet Alfa for Life-Threatening Bleeding Following Factor Xa Inhibitor Treatment
JACC Asia · 2026
- Asundexian Versus Apixaban in Patients With Atrial Fibrillation
Health Science Reports · 2026
- Anticoagulant strategies in atrial fibrillation and chronic kidney disease: From pathophysiology to clinical practice
Journal of Translational Critical Care Medicine · 2026
- Simultaneous TAVR and EVAR for Severe Aortic Regurgitation With Giant Abdominal Aortic Aneurysm
JACC Case Reports · 2026
- 16: COMPARING BRANDED 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATES FOR REVERSAL IN INTRACRANIAL BLEEDING
Critical Care Medicine · 2026
- Apixaban-induced anaphylaxis
BMJ Case Reports · 2026
- Non-Enzymatic Isolation of Stromal Vascular Fraction (SVF) And Adipose-Derived Stem Cells (ADSCs): A Systematic Methodological Review and Meta Analysis
Biomedical Research and Therapy · 2026
- Discontinuation of Anticoagulation Therapy After Atrial Fibrillation Ablation: The ALONE-AF and OCEAN Studies
European Heart Journal Supplements · 2026
- Precise atorvastatin delivery by cardiac homing peptide functionalized nanoliposomes for myocardial damage repair after myocardial infarction
Nanomedicine · 2026
- A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
New England Journal of Medicine · 2026
- Coagulation assays for assessing the bypassing of factor Xa direct oral anticoagulants using VMX-C001
Research and Practice in Thrombosis and Haemostasis · 2026
- Atorvastatin Protects Against Deleterious Carfilzomib-Induced Transcriptional Changes in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
International Journal of Molecular Sciences · 2026
- Factors influencing the inappropriate dosing of rivaroxaban and edoxaban in Chinese hospitalized patients with atrial fibrillation
Frontiers in Cardiovascular Medicine · 2026
- Angiotensin-Converting Enzyme (ACE) Inhibitors and Statins Mitigate Negative Cardiovascular and Pulmonary Effects of Particulate Matter in a Mouse Exposure Model
Antioxidants · 2026
- Hemorrhagic risk of concomitant direct oral anticoagulants and fluoroquinolones: integration of pharmacovigilance and therapeutic drug monitoring
Frontiers in Pharmacology · 2026
- Lipophilic but not hydrophilic statin therapy improves cardiodynamics without affecting skeletal muscle morphology or function in geriatric Wistar rats
PLoS ONE · 2026
- Cardiac remodelling in type 2 diabetes: Pathophysiological mechanisms and opportunities for multiscale computational modelling and simulation
The Journal of Physiology · 2026
- Rivaroxaban Initiation Timing and Clinical Outcomes After Acute Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation: An IPTW-Based Cohort Study
Clinical and Applied Thrombosis/Hemostasis · 2026
- Discrepant Outcomes of Direct Oral Anticoagulant Trials in Device-Detected Atrial Fibrillation after Stroke: Insights from NOAH-AFNET 6 and ARTESIA
Clinical and Applied Thrombosis/Hemostasis · 2026
- Comparative pharmacokinetics of a candesartan/amlodipine/atorvastatin fixed-dose combination 8 mg/5 mg/10 mg versus separate tablets in healthy subjects: a partial replicated crossover study
Translational and Clinical Pharmacology · 2026
- Effects of rosuvastatin and atorvastatin treatment on ET-1, ADMA, and safety efficacy in elderly patients with coronary heart disease combined with hyperlipidemia
Open Life Sciences · 2026
- Investigation of cardioprotective effects of <i>Leea rubra</i> Blume leaves on isoproterenol-induced left ventricular hypertrophy in mice
Journal of Herbmed Pharmacology · 2026
- Angiotensin-converting enzyme (ACE) inhibitors and statins mitigate negative cardiovascular and pulmonary effects of particulate matter in a mouse exposure model
2026
- Drug–Drug Interaction Signals for Apixaban‐Associated Haemorrhage in Atrial Fibrillation and Thromboembolic Disorders: A Disproportionality Analysis of the FAERS Database
Journal of Interventional Cardiology · 2026
- Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
Clinical and Applied Thrombosis/Hemostasis · 2026
- Effect of loading dose atorvastatin on postoperative cardiovascular events in elderly patients with acute myocardial infarction undergoing percutaneous coronary intervention
American Journal of Translational Research · 2026
- Atorvastatin suppresses high-risk colorectal adenomas via reprogramming of lipid metabolism and Inhibition of stemness
Scientific Reports · 2025
- Effects of Bariatric Surgery on the Pharmacokinetics of Cardiovascular Drugs: A Systematic Review and Meta-Analysis
Obesity Surgery · 2025
- Can in silico models predict drug-induced cardiac risk in vulnerable populations?
Toxicology Reports · 2025
- Histological And Physiological Evaluation Of Atorvastatin In Mitigating Atherosclerosis A Study Of Vascular Remodeling
The Review of Diabetic Studies · 2025
- Changes in Repolarizing Currents in Mouse Cardiomyocytes Following Chronic Atorvastatin Exposure
Bulletin of Experimental Biology and Medicine · 2025
- Edoxaban for stroke prevention in patients with atrial fibrillation: Of randomized and real-world evidence
Indian Pacing and Electrophysiology Journal · 2025
- Inhibition of FXa could be a novel therapeutic target associated with hypoxia-associated tumor behavior?
Discover Oncology · 2025
- A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis
Scientific Reports · 2025
- Association Between History of Rhythm Control Therapy and Clinical Outcomes in Atrial Fibrillation Patients With Stable Coronary Artery Disease: A Sub‐Analysis of the <scp>AFIRE</scp> Trial
Journal of Arrhythmia · 2025
- Towards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study
Frontiers in Drug Discovery · 2025
- Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
New England Journal of Medicine · 2025
- Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy
JAMA Cardiology · 2025
- Evolocumab before percutaneous coronary intervention for acute myocardial infarction: Design of the AMUNDSEN trial
American Heart Journal · 2025
- Upgrading the STEMI emergency kit: a meta-analysis of randomized controlled trials
European Heart Journal · 2025
- The reduction of clot lysis time on statins is associated with lipid plaque parameters in optical coherence tomography in acute myocardial infarction
European Heart Journal · 2025
- Underuse of statins and antiplatelet therapy in high-risk cardiovascular patients: sex-based differences
European Heart Journal · 2025
- Atorvastatin and left ventricular global longitudinal strain during anthracycline-based chemotherapy
European Heart Journal · 2025
- Acute Renal Artery Thrombosis Following Delayed Postoperative Anticoagulation in Atrial Fibrillation: A Case Report Supporting Apixaban Monotherapy
Cureus · 2025
- The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus
Global Heart · 2025